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The efficacy of erythromycin was assessed in the treatment of 14
children aged 4 to 13 years with refractory chronic constipation, and
presenting megarectum and fecal impaction. A double-blind, placebo-
controlled, crossover study was conducted at the Pediatric Gastroen-
terology Outpatient Clinic of the University Hospital. The patients
were randomized to receive placebo for 4 weeks followed by erythro-
mycin estolate, 20 mg kg-1 day-1, divided into four oral doses for
another 4 weeks, or vice versa. Patient outcome was assessed accord-
ing to a clinical score from 12 (most severe clinical condition) to 0
(complete recovery). At enrollment in the study and on the occasion of
follow-up medical visits at two-week intervals, patient score and
laxative requirements were recorded. During the first 30 days, the
mean ± SD clinical score for the erythromycin group (N = 6) decreased
from 8.2 ± 2.3 to 2.2 ± 1.0 while the score for the placebo group (N =
8) decreased from 7.8 ± 2.1 to 2.9 ± 2.8. During the second crossover
phase, the score for patients on erythromycin ranged from 2.9 ± 2.8 to
2.4 ± 2.1 and the score for the patients on placebo worsened from 2.2
± 1.0 to 4.3 ± 2.3. There was a significant improvement in score when
patients were on erythromycin (P < 0.01). Mean laxative requirement
was lower when patients ingested erythromycin (P < 0.05). No eryth-
romycin-related side effects occurred. Erythromycin was useful in this
group of severely constipated children. A larger trial is needed to fully
ascertain the prokinetic efficacy of this drug as an adjunct in the
treatment of severe constipation in children.
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Constipated children presenting fecal im-
paction and soiling show disrupted colonic
propulsive motility (1) and are usually re-
fractory to laxative and fiber therapy (2).
Few prokinetic drugs have been evaluated in
these patients. Cisapride has some effect on
constipation (3), but the side effects related
to cardiac dysrhythmias have restricted its
use (4). Prucalopride, a selective 5-hydroxy-
tryptamine receptor agonist, accelerates co-
lonic transit in adults with constipation, but
has not yet been tested in children (5).
Erythromycin is a prokinetic agent that
acts via motilin receptors on cholinergic neu-
rons and on smooth muscle cells present in
the human gastrointestinal system (6). A num-
ber of studies carried out to investigate the
prokinetic action of erythromycin in chil-
dren (7) have obtained considerable evidence
that the drug may be a useful prokinetic
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agent in feeding intolerance associated with
prematurity, in low birth weight infants re-
covering from abdominal surgery, and in
older children with a variety of other gas-
trointestinal disorders (8-11). Only one ran-
domized placebo-controlled trial has been
conducted (12) and there are no clinical
studies on the use of erythromycin in chil-
dren with constipation.
The objective of the present study was to
assess the efficacy of erythromycin as an
adjunct in the treatment of chronic, refrac-
tory constipation in children.
A double-blind, placebo-controlled cross-
over study was conducted at the State Uni-
versity of Campinas Medical School Hospi-
tal. Children who attended the Pediatric Gas-
troenterology Clinic from October 1998 to
September 2000 were eligible for the study.
The Hospital Ethics Committee approved
the study and informed consent was ob-
tained from the parents of all children.
Subjects were randomized to receive pla-
cebo or erythromycin first. Erythromycin
estolate, 20 mg kg-1 day-1, divided into four
doses, was administered orally every 6 h
before meals. The maximum dose used was
1000 mg. Follow-up medical visits were
scheduled every two weeks. Only patients
with a chronic and sometimes lifelong his-
tory of constipation were included, consid-
ering the following enrollment criteria: 1)
stool passage frequency less than three times
per week, 2) presence of diurnal and noctur-
nal soiling, 3) presence of fecal impaction
defined as a filled rectum and identified by a
palpable abdominal mass or by digital rectal
examination, 4) no previous or current dis-
ease known to affect gastrointestinal motil-
ity, 5) no history of gastrointestinal sub-
occlusive episodes, 6) absence of mechani-
cal obstruction as determined by barium en-
ema, 7) absence of outlet obstruction evalu-
ated by defecography, and 8) presence of
rectal anal inhibitory reflex detected by ano-
rectal manometry and a normal balloon ex-
pulsion test.
Liver function was evaluated by deter-
mining serum transaminase, alkaline phos-
phatase and gamma-glutamyltransferase ac-
tivity, before starting medication and at the
end of the study.
After the first medical visit, the patient
was admitted to the hospital for fecal impac-
tion removal by consecutive enemas. After
colonic cleansing, an oral osmotic laxative
was prescribed as maintenance therapy to
establish a regular frequency of bowel move-
ments. Lactulose (667 mg/ml) or magne-
sium hydroxide (80 mg/ml) was adminis-
tered at a daily dose of 2 ml/kg, with a
maximum dose of 60 ml. Parents were in-
structed to use a saline-glycerol enema when
there was no spontaneous stool movement
after a 72-h period. Patients were instructed
to sit on the toilet for 5 to 10 min after each
meal in order to take advantage of the
gastrocolonic response. After the first medi-
cal visit the patients returned every 15 days
when they were asked about abdominal colic,
nausea, vomiting, epigastric pain, diarrhea,
jaundice, choluria, skin rash, and symptoms
related to bowel movements.
A score scale (Table 1) was used to per-
mit comparison of clinical evaluation data.
The score design was based on a validated
symptom scoring system for constipated
adults (13). An initial score value was ob-
tained just before impaction removal and
every 15 days thereafter until the 8th week of
the study. As an example, a child presenting
fecal impaction (2 points), soiling (2 points),
reporting pain at stool passage occasionally
(1 point), scybalous fecal consistency (2
points), and stool frequency less than one
per week (2 points) received an initial score
of 9. The score scale included the require-
ment of a laxative. During the study, the
initially prescribed laxative dose (2 ml kg-1
day-1) was maintained, reduced or increased
according to stool frequency, fecal consist-
ency and stool passage conditions which
occurred during the previous 2 weeks. The
laxative dose was reduced when patient men-
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tioned liquid fecal consistency and increased
evacuation in the presence of hard/scybalous
fecal consistency or a stool frequency of less
than 3 per week or enema requirement dur-
ing the previous period.
Analysis of variance for crossover stud-
ies was used to test the null hypothesis of no
difference among group means. Laxative re-
quirement was evaluated comparing the mean
doses on days 15 and 30 with the mean doses
on days 45 and 60 in each group by the
Wilcoxon test. A P value of less than 0.05
was taken to be statistically significant.
Twenty-one children fulfilled the inclu-
sion criteria and were enrolled in the trial.
Seven were excluded for the following rea-
sons: children refused to take any medica-
tion including the laxatives and the test sub-
stance (N = 3), failure to return for the
scheduled second medical visit (N = 3), and
failure to take the four daily doses of the test
drug (N = 1). Six patients completed the
study after taking the erythromycin-to-pla-
cebo sequence (group I), and 8 children com-
pleted the inverse crossover sequence pla-
cebo-to-erythromycin (group II). The clini-
cal features of the patients allocated to the
two groups were similar. Mean (± SD) age
was 9.7 ± 3.0 and 9.6 ± 3.3 years for group I
and group II, respectively. Group I included
one girl and group II, two girls. Age at onset
of constipation (mean ± SD) was 5.1 ± 3.8
years for group I, and 3.5 ± 2.6 years for
group II. Duration of constipation (mean ±
SD) was 4.6 ± 3.6 and 5.8 ± 1.9 years for
group I and group II, respectively.
Patients reported no side effects and did
not present laboratory evidence of hepatic
toxicity.
The score for the erythromycin group
(mean ± SD) decreased from 8.2 ± 2.3 to 2.2
± 1.0 in the first 30 days, while in the placebo
group it decreased from 7.8 ± 2.1 to 2.9 ±
2.8. In the second crossover phase, the score
for patients on erythromycin ranged from
2.9 ± 2.8 to 2.4 ± 2.1 and the score for those
on placebo worsened from 2.2 ± 1.0 to 4.3 ±
Figure 1. Clinical score outcome. Longitudinal scores (mean ± SD) for group I (erythromy-
cin-to-placebo sequence, E/P, squares), and group II (placebo-to-erythromycin sequence,
P/E, circles) during the crossover study are illustrated.
2.3. Figure 1 shows that patient outcome was
quite similar in the two groups during the
first month of the study. In the second cross-
over phase, mean scores showed a progres-
sive divergence. In patients on erythromy-
cin, mean scores continued to be favorable,
whereas they worsened significantly in pa-
tients on placebo. Two group I patients pre-
sented relapses of fecal impaction in the
second crossover phase.
The P values for the hypothesis tested by
analysis of variance for a crossover study
were the following: 1) the mean score of
group I during the period of erythromycin
ingestion was similar to that of group II
Table 1. Parameters used to assess clinical outcome and respective clinical scores.
Value Weekly Fecal Soiling Pain or Fecal Laxative
stool impaction difficulty at consistency  dose
frequency stool passage (ml kg-1 day-1)
0 ≥3 Absent Absent Never Soft/loose/ No
liquid
1 1-2 - - Occasional Hard <1
2 <1 Present Present Often Scybalous 1-2
3 - - - Occasional enema - >2
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during the same period. The groups were
also similar during the period of placebo
ingestion (P = 0.9456). 2) There was no
residual drug effect (P = 0.6973) indicating
that the sequence of treatment did not inter-
fere with the results and that erythromycin
was equally effective when ingested in ei-
ther 4-week period. 3) The mean scores of
the 14 patients during the study (days 0, 15,
30, 45 and 60) did not differ significantly (P
= 0.0517) in the test for treatment versus
time interaction. 4) Comparison of the mean
scores of the groups in the first and in the
second 4-week periods indicated a signifi-
cant difference (P = 0.0001). Thus, the meas-
ures for treating constipation were effective
in alleviating the severity of the condition
over a 60-day period. 5) Comparison of mean
scores for the placebo and erythromycin pe-
riods indicated a significant difference, with
a lower score being observed during the
period of erythromycin ingestion regardless
of the sequence of ingestion (P = 0.0058).
Concerning the laxative requirements, the
mean laxative dose during the erythromycin
period was lower than during the placebo
period (P = 0.03) in group I. Patients in group
II required less laxative while taking the
prokinetic (P = 0.01).
Animal and clinical studies concerning
erythromycin have demonstrated a prokinetic
effect of the drug on the gastrointestinal tract
at doses lower than those for antibacterial
activity, usually less than a quarter of the
antibiotic dose. Intravenous administration
of 1 mg/kg induces a migratory motor com-
plex, while higher doses (7-10 mg/kg) result
in sustained contractile activity in the small
bowel and suppression of phase III activity
(14). Studies on children have tested a wide
variety of doses since the optimum dose for
a prokinetic activity is not known. Most
studies used a 1- to 3-mg/kg dose for intrave-
nous administration and a 5-mg/kg dose by
the oral route (7). During the last ten years,
about two dozen pediatric clinical trials were
conducted, with nine using the oral or en-
teral route. Most studies have tested intrave-
nous administration since they included criti-
cally ill patients, mainly with gut dysmotility
or prematurity. The prokinetic effect is sig-
nificant when the drug is given orally in the
form of ethylsuccinate or estolate, or intra-
venously as lactobionate. Significantly, no
serious adverse effects have been reported in
these studies, although fatal ventricular dys-
rhythmia has followed intravenous adminis-
tration of antibiotic doses to neonates (15).
There are no reports of this complication
when erythromycin is given at a prokinetic
dose. Hepatotoxicity is a very rare phenom-
enon in children. It has been reported with
the use of erythromycin stearate and ethyl-
succinate, and the highest incidence appears
to be associated with estolate (16). The he-
patic toxic effects usually subside upon with-
drawal of erythromycin and long-term liver
disease has not been reported.
In the present crossover study, children
with chronic refractory constipation experi-
enced a significant relief after fecal impac-
tion removal, regular drug therapy and strict
supervision. After the first 4 weeks on thera-
py, the children showed significantly im-
proved clinical parameters while ingesting
erythromycin.
The gastric motor effect of erythromycin
has been well established in healthy subjects
and in patients with upper gastrointestinal
motility dysfunction, but few data are avail-
able for the small and large intestine. Studies
on healthy adults have indicated an accelera-
tion of intestinal and colonic transit time
(17). The identification of motilin receptors
in the human colon (18) has stimulated in
vitro studies and clinical trials on constipa-
tion. Oral erythromycin increased the stool
frequency and significantly reduced the total
colonic transit time in 11 constipated adults
(19). Stenson et al. (11) used erythromycin
in food-intolerant preterm infants and, al-
though the drug was not useful in establish-
ing enteral feeding, the patients were pre-
scribed fewer glycerin suppositories for con-
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stipation.
In the current study, the effects of eryth-
romycin were tested during a 60-day period
after fecal impaction removal. Conducting
the study over this period of time permitted
the observation of the effect of erythromycin
during a homogeneous stage of therapy
among patients. It was hypothesized that to
study the prokinetic effect just after impac-
tion removal would be more adequate since
it is known that relapses are more probable
and frequent during this period of constipa-
tion therapy (2). During the second cross-
over phase the difference between groups
became more evident. Erythromycin seems
to have been more useful in the second phase
when patients on placebo presented worse
scores even when using higher doses of laxa-
tive. In spite of closer mean scores during the
first 30 days of the study, patients on eryth-
romycin showed lower laxative requirements
than those on placebo. Regular bowel move-
ments and cessation of impaction relapses
are considered to be improvement param-
eters (20). Usually, regular stool passage is
established with large doses of laxatives re-
quired in the presence of poor propulsive
colonic motility. A lower laxative require-
ment to obtain regular stool passage may in-
dicate a better colonic propulsive competence.
Within the limitations of a small sample,
these data indicate the potential importance
of erythromycin for alleviating symptoms in
children with chronic, severe constipation.
More extensive studies should be performed,
with lower doses, fewer daily doses or using
selective motilin agonists to fully assess the
usefulness of erythromycin for treating con-
stipation.
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